Location out of bounds
Radial
Radial

Newsroom

Resources for journalists

All Press Releases
Technician reviews bag of new pathogen reduced platelets.

Versiti among first in U.S. to offer pathogen reduced platelets

Versiti – February 21, 2018

Milwaukee – February 21, 2018 – Versiti, Inc., a national leader in blood health innovation, is among the first in the United States to provide pathogen reduced platelets that reduce the risk of infection and lead to safer transfusions for patients. Versiti produced its first pathogen reduced platelets in January 2018 at BloodCenter of Wisconsin, part of Versiti. The platelets were provided to one of Versiti’s hospital partners in Wisconsin. 

Because platelet transfusions are on the rise due to an increase in trauma situations, transplantation, and in treatment of cancer patients, as well as to prevent and treat bleeding in patients who are thrombocytopenic, the importance of providing pathogen reduced platelets is becoming increasingly important. Versiti, which already utilizes multiple tests and every available technology to ensure the safety of the blood supply, took a leading role in the implementation of pathogen reduction technology.

“Versiti is dedicated to patient and transfusion safety, continually seeking novel technologies that improve the safety of the blood and blood components we distribute and provide to our hospital partners,” said Versiti Chief Medical Officer Thomas Abshire, M.D. “This technology helps advance transfusion medicine and creates improved outcomes for patients receiving platelet transfusions.”  

This innovative technology reduces the risk for infection and disease transmission in transfused patients. By using a special additive, the technology inactivates bacteria, viruses and other pathogens as well as leukocytes that may be present in donated blood. The technology also preserves cell and protein quality, and may offer additional benefits, including platelet shelf-life extension, and negate the requirement for gamma-irradiation and testing for cytomegalovirus of platelets.

Versiti anticipates expanding production of pathogen reduced platelets at its BloodCenter of Wisconsin location, and at all Versiti locations in the near future, to serve additional hospitals throughout the state and across the country.

About Versiti

Versiti, a national leader in blood health innovation, was formed with the mission to improve the health of patients and enable the success of our health care partners nationally. We provide innovative, value added solutions in the fields of transfusion medicine, transplantation, and blood-related diseases to meet the needs of each of our customers. The collective efforts across Versiti result in improved patient outcomes, expanded access to care and cost efficiencies for health care systems nationwide. For more information, visit www.versiti.org.

###

Contact Us

Fay Spano

Director, Public Relations and Corporate Communications
Email (414) 937-6124

Other Press Releases

Versiti Blood Center of Ohio

Gratitude extended to blood donors as the 2019 Blood Battle comes to end

December 2, 2019

The final score: University of Michigan – 1,938 donations, The Ohio State University –1,525 donations.

Read More
3d illustration of an activated platelets

Versiti Launches New Test to Improve HIT Diagnostics, Reduce Progression to Deadly Conditions Caused

December 2, 2019

Versiti, Inc., a national leader in blood health innovation, is excited to announce the launch of its new P-Selectin Expression Assay (PEA).

Read More
Versiti Logo

Versiti Blood Center of Wisconsin to Host One of the Largest High School Blood Drives in the State

December 2, 2019

West Bend blood donors can help patients in need at Versiti Blood Center of Wisconsin’s upcoming blood drive on Wednesday, Dec. 11 at West High School.

Read More
ic-arrow-right
x

This website uses cookies to ensure you get the best experience on our website. Learn more